B&L Asset Management LLC Purchases New Holdings in Pfizer Inc. (NYSE:PFE)

B&L Asset Management LLC acquired a new position in Pfizer Inc. (NYSE:PFE) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,703 shares of the biopharmaceutical company’s stock, valued at approximately $397,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Olistico Wealth LLC bought a new position in Pfizer during the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the second quarter valued at $29,000. Gladius Capital Management LP increased its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP purchased a new position in shares of Pfizer in the 2nd quarter worth about $31,000. Finally, Financial Connections Group Inc. bought a new position in Pfizer in the 2nd quarter worth about $34,000. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.5 %

Shares of PFE stock opened at $26.21 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $148.53 billion, a price-to-earnings ratio of 35.42, a PEG ratio of 0.71 and a beta of 0.67. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a fifty day moving average price of $27.83 and a 200-day moving average price of $28.49.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) earnings per share. The business’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.41%. Pfizer’s payout ratio is currently 227.03%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Citigroup assumed coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.